

103^D CONGRESS
1ST SESSION

H. R. 2079

To amend the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act with respect to myelogram-related arachnoiditis.

IN THE HOUSE OF REPRESENTATIVES

MAY 11, 1993

Mr. TRAFICANT introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To amend the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act with respect to myelogram-related arachnoiditis.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Myelogram-Related
5 Arachnoiditis Amendments of 1993”.

6 **SEC. 2. ADULTERATED MYELOGRAMS.**

7 Section 501 of the Federal Food, Drug, and Cosmetic
8 Act (21 U.S.C. 351) is amended by adding at the end the
9 following:

1 “(j) If it is a myelogram involving the use of
2 Pantopaque, Amipaque, Omipacque, or Isovue.”.

3 **SEC. 3. MYELOGRAM-RELATED ARACHNOIDITIS; ACTIVI-**
4 **TIES OF NATIONAL INSTITUTE OF NEURO-**
5 **LOGICAL DISORDERS AND STROKE.**

6 Subpart 10 of part C of title IV of the Public Health
7 Service Act (42 U.S.C. 285j et seq.) is amended by adding
8 at the end the following section:

9 “MYELOGRAM-RELATED ARACHNOIDITIS

10 “SEC. 459A. With respect to individuals who have
11 undergone the diagnostic procedure known as a
12 myelogram and who have subsequently developed cases of
13 arachnoiditis, the Director of the Institute shall—

14 “(1) conduct or support a study to develop an
15 estimate of the number of such individuals in the
16 United States;

17 “(2) conduct or support research to determine
18 the extent to which such cases are associated with
19 the use of such procedure; and

20 “(3) conduct or support research on treatments
21 for such cases in such individuals, including treat-
22 ments to manage pain.”.

○